Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Genes 2013, 4(3), 457-484; doi:10.3390/genes4030457
Review

Antisense Gene Silencing: Therapy for Neurodegenerative Disorders?

1,2,*  and 1,2
Received: 20 May 2013; in revised form: 11 July 2013 / Accepted: 13 August 2013 / Published: 10 September 2013
(This article belongs to the Special Issue Gene Silencing)
View Full-Text   |   Download PDF [942 KB, uploaded 10 September 2013]   |   Browse Figures
Abstract: Since the first reports that double-stranded RNAs can efficiently silence gene expression in C. elegans, the technology of RNA interference (RNAi) has been intensively exploited as an experimental tool to study gene function. With the subsequent discovery that RNAi could also be applied to mammalian cells, the technology of RNAi expanded from being a valuable experimental tool to being an applicable method for gene-specific therapeutic regulation, and much effort has been put into further refinement of the technique. This review will focus on how RNAi has developed over the years and how the technique is exploited in a pre-clinical and clinical perspective in relation to neurodegenerative disorders.
Keywords: RNA interference; neurodegenerative disorders; CNS RNA interference; neurodegenerative disorders; CNS
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Nielsen, T.T.; Nielsen, J.E. Antisense Gene Silencing: Therapy for Neurodegenerative Disorders? Genes 2013, 4, 457-484.

AMA Style

Nielsen TT, Nielsen JE. Antisense Gene Silencing: Therapy for Neurodegenerative Disorders? Genes. 2013; 4(3):457-484.

Chicago/Turabian Style

Nielsen, Troels T.; Nielsen, Jørgen E. 2013. "Antisense Gene Silencing: Therapy for Neurodegenerative Disorders?" Genes 4, no. 3: 457-484.



Genes EISSN 2073-4425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert